ARDS in Children and ECMO Initiation Strategies Impact on Neurodevelopment (ASCEND)
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 550
- 试验地点
- 194
- 主要终点
- Change in health-related quality of life
研究概览
简要总结
ASCEND researchers are partnering with families of children who receive extracorporeal membrane oxygenation (ECMO) after a sudden failure of breathing named pediatric acute respiratory distress syndrome (PARDS). ECMO is a life support technology that uses an artificial lung outside of the body to do the lung's work. ASCEND has two objectives.
The first objective is to learn more about children's abilities and quality of life among ECMO-supported children in the year after they leave the pediatric intensive care unit. The second objective is to compare short and long-term patient outcomes in two groups of children: one group managed with a mechanical ventilation protocol that reserves the use of extracorporeal membrane oxygenation (ECMO) until protocol failure to another group supported on ECMO per usual care.
详细描述
Decades after extracorporeal membrane oxygenation (ECMO) was first used to support children with severe pediatric acute respiratory distress syndrome (PARDS), pediatric intensivists lack both prospective studies of long-term outcomes in ECMO for PARDS and well-powered studies comparing the impact of ECMO initiation strategies on mortality and morbidity. While clinicians lack the equipoise necessary to randomize ECMO in dying children, there is uncertainty on if and when it is best to initiate ECMO to preserve survival, functioning, and quality of life. To determine if and when ECMO should be initiated in children with severe PARDS, it is necessary to compare the long-term outcomes in ECMO supported children to otherwise similar children who did not receive ECMO at the same threshold if at all.
An opportunity to address this question is provided by NHLBI-funded Prone and Oscillation Pediatric Clinical Trial (PROSpect) and the ECMO registry, Extracorporeal Life Support Organization (ELSO). PROSpect is an existing randomized clinical trial testing the impact of supine/prone positioning and conventional mechanical ventilation/high-frequency oscillatory ventilation on short and long-term clinical outcomes in 1,000 children with severe PARDS. PROSpect manages subjects with a rigorous protocol that reserves ECMO for protocol failure. The ELSO Registry includes children receiving usual care ECMO, initiated at the discretion of the intensivist.
ASCEND harmonizes PROSpect and ELSO data collection and prospectively measures functional status and quality of life via surveys in an additional 550 children with severe PARDS from ELSO sites. ASCEND measures children's abilities and quality of life when the child was in their normal state of health (just prior to being hospitalized), at discharge from the pediatric intensive care unit, and at 1-month, 3-months, 6-months, and 12-months after discharge from the pediatric intensive care unit. After enrollment of the usual care ECMO (in ELSO) and PROSpect's protocolized therapies (from the PROSpect clinical trial) is complete, then ASCEND will match similarly critically ill children based on their propensity to receive usual care ECMO.
ASCEND combines real-world observational data (from ELSO) and a randomized clinical trial (from PROSpect) to address two specific aims.
Aim 1: The study will test the hypotheses that one year after children receive usual care ECMO for PARDS, there will be a decline in long-term functional status and health-related quality of life as well as an increase in the proportion of children receiving respiratory support.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 14 Days 至 20 Years（Child, Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Time between intubation and ECMO cannulation is less than 240 hours (10 days)
- •ECMO support type is respiratory (VV or VA cannulation)
- •Chest radiograph with bilateral lung disease
- •Moderate or severe pediatric ARDS as measured by oxygenation index or oxygen saturation index after intubation and prior to ECMO cannulation:
- •One OI ≥ 16 or Two OIs ≥ 12 and ≤ 16 at least four hours apart or Two OSIs ≥ 10 at least four hours apart or One OI ≥ 12 and ≤ 16 and One OSI ≥ 10 at least four hours apart
排除标准
- •Previously enrolled in PROSpect
- •Perinatal related lung disease
- •Congenital diaphragmatic hernia or congenital/acquired diaphragm paralysis
- •Respiratory failure caused by cardiac failure or fluid overload
- •Cyanotic congenital heart disease
- •Cardiomyopathy
- •Primary pulmonary hypertension (PAH)
- •Unilateral lung disease
- •Intubated for status asthmaticus
- •Obstructive airway disease
- •Bronchiolitis obliterans
- •Post hematopoietic stem cell transplant
- •Post lung transplant
- •Home ventilator dependent
- •Neuromuscular respiratory failure
- •Head trauma: (managed with hyperventilation)
- •Intracranial bleeding
- •Unstable spine, femur or pelvic fractures
- •Acute abdominal process/open abdomen
- •Family/medical team have decided to not provide full support
- •Enrolled in interventional clinical trial: not approved for co-enrollment; does not include cancer protocols.
- •Known pregnancy
研究组 & 干预措施
Usual care ECMO Cohort
The cohort will be comprised of 550 patients, aged 14 days to 20 years, who go on extracorporeal membrane oxygenation (ECMO) support due to pediatric acute respiratory distress syndrome (PARDS) at physician discretion. Patients with qualifying PARDS must have one oxygenation index (OI) ≥ 16 or two OIs 12 ≥ to < 16 (at least 4 hours apart) or two oxygenation saturation indexes (OSIs) ≥ 10 (at least 4 hours apart) or one OI 12 ≥ to < 16 and one OSI > 10 (at least 4 hours apart) Subjects must be on mechanical ventilation for less than 240 hours (10 days) prior to cannulation. These measures must be after endotracheal intubation and before ECMO start. Chest radiograph prior to ECMO must show bilateral lung disease.
Subjects cannulated on ECMO for no more than 96 hours prior to gaining consent.
干预措施: ECMO support (Device)
PROSpect protocolized therapies cohort
The cohort will be comprised of 1000 patients, aged 14 days to 20 years, who are endotracheally intubated for PARDS. Patients with qualifying PARDS must have one oxygenation index (OI) ≥ 16 or two OIs 12 ≥ to < 16 (at least 4 hours apart) or two oxygenation saturation indexes (OSIs) ≥ 10 (at least 4 hours apart) or one OI 12 ≥ to < 16 and one OSI > 10 (at least 4 hours apart). These measures must be after endotracheal intubation. Chest radiograph must show bilateral lung disease. Patient must be enrolled in a clinical trial Prone and Oscillation Pediatric Clinical Trial (PROSpect) NCT01515787 which is distinct from ASCEND.
PROSpect is a response adaptive randomized clinical trial, testing the impact of supine/prone positioning and conventional mechanical ventilation/high-frequency oscillatory ventilation on short and long-term clinical outcomes in children with severe PARDS. PROSpect manages severe PARDS subjects using a rigorous protocol that reserves ECMO for protocol failure.
干预措施: PROSpect protocolized therapies (Other)
结局指标
主要结局
Change in health-related quality of life
时间窗: baseline and 1 year after pediatric intensive care unit discharge
This primary natural history outcome is measured among usual care ECMO patients. This outcome is the change in the health-related quality of life as measured at baseline and 12 months after PICU discharge. The instrument is the age-appropriate Version 4.0 Pediatric Quality of Life Inventory (PedsQL 4.0) generic core scales for acute illness. PedsQL 4.0 Generic Core Scales and Infant Scales - Acute Version are parent proxy-report scales. The scales ranges from 0 to 100, with higher scores indicating fewer problems. PedsQL 4.0 Generic Core Scales is a 23-item scale with 4 domains: physical functioning, emotional functioning, social functioning, and school functioning. The PedsQL Infant Scales consist of 36-45 questions, depending on age, with 5 domains: physical functioning, physical symptoms, emotional functioning, social functioning, and cognitive functioning.
Change in functional status
时间窗: baseline and 1 year after pediatric intensive care unit discharge
This primary natural history outcome is measured among usual care extracorporeal membrane oxygenation (ECMO) patients. This outcome is the change in functional status as measured at baseline and 12 months after pediatric intensive care unit (PICU) discharge. The instrument is the functional status scale score. The baseline measure will be made within 96 hours of ECMO initiation and reflect patient's status in the week prior to ECMO. The Functional Status Scale (FSS) is a valid and reliable assessment method to quantify functional status. The FSS includes 6 domains: mental status, sensory functioning, communication, motor function, feeding, and respiratory. Scores for each domain range from 1 (normal) to 5 (very severe dysfunction); total scores range from 6 to 30 with higher scores reflecting worse functioning.
The proportion of children with a new morbidity
时间窗: baseline and 1 year after pediatric intensive care unit discharge
This primary natural history outcome is measured among usual care ECMO patients. A new morbidity is defined as a change in the functional status scale score instrument by 3 or more, as previously described. This outcome will report the proportion of children who acquire a new morbidity as measured at baseline and 12 months after PICU discharge. The Functional Status Scale (FSS) is a valid and reliable assessment method to quantify functional status. The FSS includes 6 domains: mental status, sensory functioning, communication, motor function, feeding, and respiratory. Scores for each domain range from 1 (normal) to 5 (very severe dysfunction); total scores range from 6 to 30 with higher scores reflecting worse functioning.
All-cause mortality at hospital discharge or 90-days
时间窗: 90 days after the day of illness on which patients from the two cohorts are matched
This primary comparative short-term outcome is measured among both usual care ECMO and Prone and Oscillation Pediatric Clinical Trial (PROSpect) protocolized therapy groups. The outcome compares the 90-day mortality for matched children in the two groups. The endpoint is 90 days after the day of illness on which patients from the two cohorts are matched or hospital discharge.
Comparative change in one-year functional status
时间窗: baseline and 1 year after pediatric intensive care unit discharge
This primary comparative long-term outcome is measured among both usual care ECMO and PROSpect protocolized therapy groups. The outcome compares the change in the functional status as measured at baseline and 12 months after PICU discharge between matched children in the two groups. The instrument is the functional status scale score. The Functional Status Scale (FSS) is a valid and reliable assessment method to quantify functional status. The FSS includes 6 domains: mental status, sensory functioning, communication, motor function, feeding, and respiratory. Scores for each domain range from 1 (normal) to 5 (very severe dysfunction); total scores range from 6 to 30 with higher scores reflecting worse functioning.
Comparative change in one-year health-related quality of life
时间窗: baseline and 1 year after pediatric intensive care unit discharge
This primary comparative long-term outcome is measured among both usual care ECMO and PROSpect protocolized therapy groups. The outcome compares the change in the health-related quality of life as measured at baseline and 12 months after PICU discharge between matched children in the two groups. The instrument is the change in the age-appropriate PedsQL 4.0 generic core scales for acute illness. PedsQL 4.0 Generic Core Scales and Infant Scales - Acute Version are parent proxy-report scales. The scales ranges from 0 to 100, with higher scores indicating fewer problems. PedsQL 4.0 Generic Core Scales is a 23-item scale with 4 domains: physical functioning, emotional functioning, social functioning, and school functioning. The PedsQL Infant Scales consist of 36-45 questions, depending on age, with 5 domains: physical functioning, physical symptoms, emotional functioning, social functioning, and cognitive functioning.
次要结局
- Change in breathing support(baseline and 1 year after pediatric intensive care unit discharge)
- Change in the physical component of health-related quality of life(baseline and 1 year after pediatric intensive care unit discharge)
- Change in family impact of the child's health(baseline and 1 year after pediatric intensive care unit discharge)
- Difference between groups in intracranial bleeding or ischemic stroke(28 days after day in illness patients are matched or during hospitalization)
- Change in pediatric overall performance category(baseline and 1 year after pediatric intensive care unit discharge)
- Change in pediatric cerebral performance category(baseline and 1 year after pediatric intensive care unit discharge)
- Change in child fatigue(baseline and 1 year after pediatric intensive care unit discharge)
- Change in the psychosocial component of health-related quality of life(baseline and 1 year after pediatric intensive care unit discharge)
- Change in one-year functional status of children suffering a neurologic injury(baseline and 1 year after pediatric intensive care unit discharge)
- Comparative difference in the change in child fatigue(baseline and 1 year after pediatric intensive care unit discharge)
- Comparative difference in new morbidity(baseline and 1 year after pediatric intensive care unit discharge)
- Difference between groups in pneumothorax(28 days after day in illness patients are matched or during hospitalization)
- Comparative difference in the change in family impact of the child's health(baseline and 1 year after pediatric intensive care unit discharge)
- Comparative difference in the change in the psychosocial component of health-related quality of life(baseline and 1 year after pediatric intensive care unit discharge)
- Comparative difference in the in change in the physical component of health-related quality of life(baseline and 1 year after pediatric intensive care unit discharge)
- Comparative change in respiratory support(baseline and 1 year after pediatric intensive care unit discharge)
研究者
Ryan Barbaro
Associate Professor of Pediatrics
University of Michigan